Identifying and reprogramming softness-driven cancer stem-like cells overcomes CAR-T cell resistance in solid tumours.
Solid tumours show substantial mechanical heterogeneity, yet how such cues influence the susceptibility of cancer cells to T cell-based therapies remains unclear. Transcriptomic analyses showed that recorder-positive cells adopt a stem-like programme, including epithelial-mesenchymal transition, hypoxia responses, oncogenic signalling and elevated stemness markers, across cancer cell lines and patient-derived samples.
Solid tumours show substantial mechanical heterogeneity, yet how such cues influence the susceptibility of cancer cells to T cell-based therapies remains unclear. Transcriptomic analyses showed that recorder-positive cells adopt a stem-like programme, including epithelial-mesenchymal transition, hypoxia responses, oncogenic signalling and elevated stemness markers, across cancer cell lines and patient-derived samples.
What the study was
- Study design
- Preclinical study
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Nature biomedical engineering
Why it surfaced
Low-signal Novel therapeutics: immunotherapy, CAR-T, targeted therapy entry (Preclinical study design); retained for topic coverage completeness.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.